Low-Grade Central Osteosarcoma
- Author: Barnaby Dedmond, MD; Chief Editor: Harris Gellman, MD more...
Background
Background
Osteosarcoma of bone is a high-grade tumor with a long-term survival rate of 60-85%. Several variants of osteosarcoma exist.[1, 2] High-grade variants include telangiectatic osteosarcoma, small-cell osteosarcoma, high-grade surface osteosarcoma, and secondary osteosarcoma. Other variants, such as low-grade central osteosarcoma (see images below), parosteal osteosarcoma, and periosteal osteosarcoma, are less aggressive entities with a lower rate of metastasis and a long-term survival rate approaching 90%. Low-grade central osteosarcoma is a rare variant of osteosarcoma that is often mistaken for fibrous dysplasia.[3] (See also the eMedicine articles Osteosarcoma, Variants and Parosteal Osteosarcoma.)
Bone scan of a low-grade central osteosarcoma of the distal femur.
Magnetic resonance image (MRI) of low-grade central osteosarcoma of the distal femur. Initial diagnosis of osteosarcoma is often difficult.[4, 5] Frequently, it is diagnosed only after a recurrence of disease in an area of bone where a diagnosis of fibrous dysplasia had previously been made.[6] Osteosarcoma has also been mistaken for other benign and malignant bone conditions, including nonossifying fibroma, well-differentiated fibrosarcoma, aneurysmal bone cyst, osteoblastoma, and desmoplastic fibroma.[7] Its rarity likely contributes to these inaccurate diagnoses.
To the author's knowledge, the largest series in the literature to date is that of Kurt and colleagues, which was published in 1990 and included 80 cases.[8] Low-grade central osteosarcoma has a better prognosis than that of high-grade osteosarcoma. (See also the eMedicine articles Fibrous Cortical Defect and Nonossifying Fibroma, Fibrosarcoma, Aneurysmal Bone Cyst [Orthopedic Surgery], Aneurysmal Bone Cyst [Radiology], Osteoblastoma [Orthopedic Surgery], and Osteoblastoma [Radiology].)
Problem
Low-grade central osteosarcoma is a rare variant of osteosarcoma that originates within the medullary cavity of bone. At histologic examination, it appears as a Broders grade 1 or grade 2 lesion. The Broders grading system was designed to determine the grade of malignancy of a given tumor on the basis of histologic features.[9] These characteristics include the following:
- Degree of cellularity
- Cellular pleomorphism or anaplasia
- Mitotic activity
- Necrosis
- Expansive or infiltrative growth
Epidemiology
Frequency
The above-mentioned study by Kurt and coauthors revealed low-grade central osteosarcoma accounts for 1.2-1.9% of all cases of osteosarcoma.[8]
Internationally, low-grade central osteosarcoma accounts for 0.7% of all cases of osteosarcoma, as reported by the Instituto de Rizzoli at the University of Bologna, Italy.
Etiology
The exact etiology of low-grade central osteosarcoma is unknown. Osteosarcomas have been experimentally induced in animals by a variety of means, including irradiation,[10] inoculation with Moloney sarcoma virus,[11] injection of bone-seeking radionucleotides,[12] and inhalation of aerosolized plutonium 238 dioxide.[13] Many of these induced tumors are well-differentiated osteosarcomas, including low-grade central osteosarcomas.
Pathophysiology
Low-grade central osteosarcomas typically develop de novo in the long bones of patients aged 20-30 years. Patients typically seek treatment when symptoms, which usually involve pain only at the site of the tumor, persist. The tumor grows locally within the bone of origin. Approximately 25-55% of these tumors invade the surrounding, adjacent soft tissue. If the tumor is not adequately resected early in its course, pulmonary metastasis may develop as a late complication.
Presentation
The mean patient age at presentation is 28.3 years. Patients with low-grade central osteosarcoma are approximately 1 decade older than patients with traditional osteosarcoma, although cases have been reported in patients aged 9-83 years.
The male-to-female ratio is 1:1; this is unlike traditional osteosarcoma, which has a male-to-female ratio of 1.4:1.
Pain is the most common symptom of low-grade central osteosarcoma; this is sometimes associated with local swelling. Typically, the duration of symptoms is long, with a mean of 1.8 years. About 5% of cases are found incidentally on radiographs obtained during an examination for reasons other than the evaluation of low-grade central osteosarcoma. Pathologic fractures are rare.
Indications
Because of its potential for metastasis and local, infiltrative destruction, the presence of a low-grade central osteosarcoma is an indication for treatment.
Relevant Anatomy
Low-grade central osteosarcoma may occur in the following locations:
- Long bones - 82.25%[14]
- Distal femur - 41%
- Proximal tibia - 12.5%
- Distal tibia - 8.75%
- Fibula - 5%
- Radius - 5%
- Proximal femur - 3.75%
- Midshaft femur - 2.5%
- Humerus - 2.5%
- Ulna - 1.25%
- Flat bones - 13.75%
- Ribs - 3.75%
- Mandible - 2.5%
- Maxilla, clavicle, occipital bone, scapula, vertebra, and ilium - 1.25% each
- Hands and feet - 4%
Contraindications
The only contraindication to the treatment of osteosarcoma is the presence of widespread metastases. Palliative treatment may then be indicated.
Rougraff BT. Variants of osteosarcoma. Curr Opin Orthop. 1999;10:485-90.
Kenan S, Ginat DT, Steiner GC. Dedifferentiated high-grade osteosarcoma originating from low-grade central osteosarcoma of the fibula. Skeletal Radiol. Apr 2007;36(4):347-51. [Medline].
Franceschina MJ, Hankin RC, Irwin RB. Low-grade central osteosarcoma resembling fibrous dysplasia. A report of two cases. Am J Orthop. Jun 1997;26(6):432-40. [Medline].
Park HR, Jung WW, Bacchini P, et al. Ezrin in osteosarcoma: comparison between conventional high-grade and central low-grade osteosarcoma. Pathol Res Pract. 2006;202(7):509-15. [Medline].
Kumar A, Varshney MK, Khan SA, Rastogi S, Safaya R. Low grade central osteosarcoma--a diagnostic dilemma. Joint Bone Spine. Oct 2008;75(5):613-5. [Medline].
Muramatsu K, Hashimoto T, Seto S, Gondo T, Ihara K, Taguchi T. Low-grade central osteosarcoma mimicking fibrous dysplasia: a report of two cases. Arch Orthop Trauma Surg. Jan 2008;128(1):11-5. [Medline].
Choong PF, Pritchard DJ, Rock MG. Low grade central osteogenic sarcoma. A long-term followup of 20 patients. Clin Orthop Relat Res. Jan 1996;198-206. [Medline].
Kurt AM, Unni KK, McLeod RA. Low-grade intraosseous osteosarcoma. Cancer. Mar 15 1990;65(6):1418-28. [Medline].
Broders AC, Hargrave R, Meyerding HW. Pathological features of soft tissue fibrosarcoma with special reference to the grading of its malignancy. Surg Gynecol Obstet. 1939;69:267.
King MA, Casarett GW, Weber DA. A study of irradiated bone. III. Scintigraphic and radiographic detection of radiation-induced osteosarcomas. J Nucl Med. May 1980;21(5):426-31. [Medline]. [Full Text].
Olson HM, Capen CC. Intratibial Moloney sarcoma virus-induced osteosarcoma in the rat: tumor incidence and pathologic evaluation. J Natl Cancer Inst. Feb 1977;58(2):433-7. [Medline].
Gössner W, Hug O, Luz A, Müller WA. Experimental induction of bone tumors by short-lived bone-seeking radionuclides. Recent Results Cancer Res. 1976;36-49. [Medline].
Hahn FF, Mewhinney JA, Merickel BS. Primary bone neoplasms in beagle dogs exposed by inhalation to aerosols of plutonium-238 dioxide. J Natl Cancer Inst. Oct 1981;67(4):917-27. [Medline].
Andresen KJ, Sundaram M, Unni KK, et al. Imaging features of low-grade central osteosarcoma of the long bones and pelvis. Skeletal Radiol. Jul 2004;33(7):373-9. [Medline].
Enneking WF. Endosteal osteosarcoma. In: Musculoskeletal Tumor Surgery. vol 2. New York, NY: Churchill Livingstone; 1983:1080-90.
Bertoni F, Bacchini P, Fabbri N, et al. Osteosarcoma. Low-grade intraosseous-type osteosarcoma, histologically resembling parosteal osteosarcoma, fibrous dysplasia, and desmoplastic fibroma. Cancer. Jan 15 1993;71(2):338-45. [Medline].
Campanacci M, Bertoni F, Capanna R, et al. Central osteosarcoma of low grade malignancy. Ital J Orthop Traumatol. Apr 1981;7(1):71-8. [Medline].
Dujardin F, Binh MB, Bouvier C, Gomez-Brouchet A, Larousserie F, Muret A, et al. MDM2 and CDK4 immunohistochemistry is a valuable tool in the differential diagnosis of low-grade osteosarcomas and other primary fibro-osseous lesions of the bone. Mod Pathol. May 2011;24(5):624-37. [Medline].
Yoshida A, Ushiku T, Motoi T, Shibata T, Beppu Y, Fukayama M, et al. Immunohistochemical analysis of MDM2 and CDK4 distinguishes low-grade osteosarcoma from benign mimics. Mod Pathol. Sep 2010;23(9):1279-88. [Medline].
Simon MA. Staging systems. In: Simon MA, Springfield D. Surgery for Bone and Soft Tissue Tumors. Philadelphia, Pa: Lippincott-Raven; 1998:47-53.
Goto T, Okuma T, Nakada I, Hozumi T, Kondo T. [Preoperative adjuvant therapy for primary malignant bone tumors]. Gan To Kagaku Ryoho. Nov 2007;34(11):1750-4. [Medline].
Unni KK, Dahlin DC, McLeod RA, et al. Intraosseous well-differentiated osteosarcoma. Cancer. Sep 1977;40(3):1337-47. [Medline].

